| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 176 | 2026 | 804 | 29.080 |
Why?
|
| Medication Errors | 139 | 2025 | 193 | 25.600 |
Why?
|
| Medical Order Entry Systems | 85 | 2025 | 108 | 22.200 |
Why?
|
| Decision Support Systems, Clinical | 103 | 2025 | 200 | 21.670 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 82 | 2025 | 266 | 14.910 |
Why?
|
| Patient Safety | 68 | 2024 | 443 | 10.530 |
Why?
|
| Drug Therapy, Computer-Assisted | 41 | 2020 | 47 | 8.160 |
Why?
|
| Medical Informatics | 38 | 2022 | 106 | 7.850 |
Why?
|
| Medical Records Systems, Computerized | 70 | 2021 | 139 | 7.680 |
Why?
|
| Primary Health Care | 68 | 2026 | 785 | 7.340 |
Why?
|
| Delivery of Health Care | 46 | 2024 | 679 | 7.040 |
Why?
|
| Physicians | 43 | 2026 | 634 | 6.640 |
Why?
|
| Safety Management | 43 | 2024 | 111 | 6.620 |
Why?
|
| Ambulatory Care | 40 | 2026 | 405 | 6.550 |
Why?
|
| Medical Errors | 51 | 2024 | 152 | 6.400 |
Why?
|
| Drug Interactions | 30 | 2024 | 241 | 6.260 |
Why?
|
| Mobile Applications | 16 | 2025 | 113 | 6.230 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 34 | 2022 | 59 | 6.000 |
Why?
|
| Humans | 791 | 2026 | 130939 | 5.800 |
Why?
|
| Quality of Health Care | 46 | 2023 | 410 | 5.490 |
Why?
|
| Patient-Centered Care | 24 | 2025 | 228 | 5.200 |
Why?
|
| Attitude of Health Personnel | 51 | 2025 | 710 | 5.170 |
Why?
|
| Internet | 28 | 2020 | 417 | 4.590 |
Why?
|
| Hospitalization | 40 | 2025 | 1925 | 4.560 |
Why?
|
| Documentation | 30 | 2026 | 121 | 4.550 |
Why?
|
| Artificial Intelligence | 19 | 2026 | 321 | 4.180 |
Why?
|
| Hospitals | 31 | 2024 | 443 | 4.140 |
Why?
|
| Diffusion of Innovation | 21 | 2020 | 84 | 3.870 |
Why?
|
| Quality Improvement | 28 | 2025 | 699 | 3.810 |
Why?
|
| Telemedicine | 25 | 2025 | 504 | 3.800 |
Why?
|
| Inpatients | 23 | 2025 | 546 | 3.770 |
Why?
|
| Intensive Care Units | 27 | 2025 | 511 | 3.700 |
Why?
|
| Middle Aged | 238 | 2026 | 28736 | 3.660 |
Why?
|
| Drug Hypersensitivity | 20 | 2025 | 97 | 3.640 |
Why?
|
| Practice Patterns, Physicians' | 35 | 2026 | 773 | 3.570 |
Why?
|
| Electronic Prescribing | 23 | 2024 | 30 | 3.570 |
Why?
|
| Quality Indicators, Health Care | 20 | 2024 | 233 | 3.500 |
Why?
|
| Drug Prescriptions | 30 | 2025 | 229 | 3.500 |
Why?
|
| Hospital Information Systems | 27 | 2021 | 42 | 3.460 |
Why?
|
| United States | 153 | 2026 | 11718 | 3.440 |
Why?
|
| Accidental Falls | 14 | 2025 | 118 | 3.430 |
Why?
|
| Attitude to Computers | 24 | 2018 | 39 | 3.400 |
Why?
|
| Physicians, Primary Care | 12 | 2026 | 99 | 3.390 |
Why?
|
| Communication | 33 | 2023 | 530 | 3.330 |
Why?
|
| Medication Systems, Hospital | 27 | 2020 | 37 | 3.250 |
Why?
|
| User-Computer Interface | 30 | 2020 | 159 | 3.240 |
Why?
|
| Aged | 173 | 2025 | 21134 | 3.200 |
Why?
|
| Adult | 210 | 2026 | 31541 | 3.180 |
Why?
|
| Health Records, Personal | 11 | 2014 | 20 | 3.170 |
Why?
|
| Male | 294 | 2026 | 64824 | 3.100 |
Why?
|
| Female | 311 | 2026 | 70759 | 3.100 |
Why?
|
| Risk Management | 20 | 2025 | 66 | 3.050 |
Why?
|
| Quality Assurance, Health Care | 26 | 2017 | 209 | 2.990 |
Why?
|
| Infusion Pumps | 10 | 2023 | 31 | 2.880 |
Why?
|
| Algorithms | 28 | 2025 | 1680 | 2.870 |
Why?
|
| Meaningful Use | 10 | 2018 | 12 | 2.780 |
Why?
|
| Massachusetts | 49 | 2025 | 117 | 2.780 |
Why?
|
| Health Care Costs | 17 | 2023 | 400 | 2.760 |
Why?
|
| Hospitals, Community | 10 | 2014 | 52 | 2.740 |
Why?
|
| Patient Satisfaction | 21 | 2020 | 461 | 2.730 |
Why?
|
| Patient Participation | 17 | 2020 | 244 | 2.710 |
Why?
|
| Analgesics, Opioid | 12 | 2025 | 468 | 2.590 |
Why?
|
| Boston | 57 | 2025 | 116 | 2.590 |
Why?
|
| DNA Replication | 14 | 2025 | 358 | 2.550 |
Why?
|
| Infusions, Intravenous | 13 | 2023 | 549 | 2.540 |
Why?
|
| Escherichia coli | 20 | 2025 | 981 | 2.510 |
Why?
|
| Outpatients | 12 | 2025 | 265 | 2.440 |
Why?
|
| Patient Care | 9 | 2025 | 99 | 2.410 |
Why?
|
| Cross-Sectional Studies | 50 | 2025 | 3799 | 2.300 |
Why?
|
| Pharmacists | 10 | 2025 | 103 | 2.240 |
Why?
|
| Academic Medical Centers | 34 | 2025 | 322 | 2.220 |
Why?
|
| Chromosomes, Bacterial | 13 | 2022 | 65 | 2.210 |
Why?
|
| Pharmaceutical Preparations | 15 | 2023 | 82 | 2.180 |
Why?
|
| Patient Portals | 9 | 2022 | 20 | 2.130 |
Why?
|
| Hospitals, Teaching | 20 | 2019 | 109 | 2.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 9 | 2025 | 339 | 2.100 |
Why?
|
| Continuity of Patient Care | 9 | 2018 | 143 | 2.100 |
Why?
|
| Pandemics | 22 | 2025 | 1157 | 2.090 |
Why?
|
| Machine Learning | 18 | 2025 | 362 | 2.070 |
Why?
|
| Physician-Patient Relations | 16 | 2022 | 434 | 2.010 |
Why?
|
| Electronic Mail | 11 | 2023 | 40 | 1.990 |
Why?
|
| Point-of-Care Systems | 9 | 2025 | 199 | 1.950 |
Why?
|
| Cell Phone | 7 | 2019 | 33 | 1.940 |
Why?
|
| Iatrogenic Disease | 17 | 2013 | 121 | 1.910 |
Why?
|
| Retrospective Studies | 95 | 2025 | 17485 | 1.900 |
Why?
|
| Information Dissemination | 7 | 2020 | 195 | 1.880 |
Why?
|
| Hypertension | 16 | 2025 | 1357 | 1.870 |
Why?
|
| Patient Harm | 4 | 2023 | 7 | 1.860 |
Why?
|
| Internal Medicine | 11 | 2025 | 123 | 1.850 |
Why?
|
| Data Collection | 30 | 2021 | 372 | 1.790 |
Why?
|
| Information Systems | 11 | 2018 | 29 | 1.780 |
Why?
|
| Workflow | 13 | 2020 | 138 | 1.760 |
Why?
|
| Reminder Systems | 19 | 2018 | 62 | 1.740 |
Why?
|
| Ambulatory Care Facilities | 12 | 2025 | 236 | 1.710 |
Why?
|
| Health Personnel | 12 | 2024 | 548 | 1.700 |
Why?
|
| Health Equity | 4 | 2024 | 79 | 1.680 |
Why?
|
| Caregivers | 8 | 2020 | 581 | 1.620 |
Why?
|
| Burnout, Professional | 8 | 2025 | 129 | 1.610 |
Why?
|
| Patient Acceptance of Health Care | 8 | 2025 | 491 | 1.610 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2023 | 151 | 1.600 |
Why?
|
| Weight Reduction Programs | 4 | 2023 | 58 | 1.590 |
Why?
|
| Ambulatory Care Information Systems | 14 | 2015 | 17 | 1.580 |
Why?
|
| Diagnostic Errors | 10 | 2025 | 340 | 1.580 |
Why?
|
| DNA, Superhelical | 2 | 2024 | 23 | 1.570 |
Why?
|
| Social Media | 5 | 2023 | 118 | 1.560 |
Why?
|
| Scleroderma, Systemic | 2 | 2025 | 129 | 1.550 |
Why?
|
| Alert Fatigue, Health Personnel | 4 | 2021 | 4 | 1.540 |
Why?
|
| Organizational Innovation | 13 | 2019 | 44 | 1.520 |
Why?
|
| Medical Staff, Hospital | 10 | 2019 | 93 | 1.500 |
Why?
|
| Patient Discharge | 15 | 2021 | 505 | 1.480 |
Why?
|
| Safety | 11 | 2018 | 215 | 1.480 |
Why?
|
| Pharmacy Service, Hospital | 11 | 2021 | 46 | 1.480 |
Why?
|
| Patient Care Team | 13 | 2022 | 558 | 1.470 |
Why?
|
| Ergonomics | 8 | 2019 | 24 | 1.460 |
Why?
|
| Drug Monitoring | 12 | 2014 | 282 | 1.450 |
Why?
|
| Asthma | 10 | 2025 | 918 | 1.450 |
Why?
|
| Aged, 80 and over | 62 | 2025 | 6862 | 1.440 |
Why?
|
| Prospective Studies | 62 | 2023 | 6443 | 1.410 |
Why?
|
| Health Information Interoperability | 4 | 2020 | 5 | 1.390 |
Why?
|
| Medicine | 8 | 2022 | 102 | 1.380 |
Why?
|
| Professional-Patient Relations | 7 | 2018 | 95 | 1.370 |
Why?
|
| Referral and Consultation | 14 | 2018 | 564 | 1.360 |
Why?
|
| Medical Records, Problem-Oriented | 5 | 2015 | 9 | 1.320 |
Why?
|
| Guideline Adherence | 14 | 2019 | 392 | 1.310 |
Why?
|
| Chronic Disease | 10 | 2017 | 1225 | 1.310 |
Why?
|
| Internationality | 8 | 2021 | 130 | 1.290 |
Why?
|
| Cross Infection | 8 | 2015 | 338 | 1.290 |
Why?
|
| Government Regulation | 4 | 2018 | 44 | 1.280 |
Why?
|
| Transgender Persons | 4 | 2024 | 68 | 1.270 |
Why?
|
| Young Adult | 40 | 2025 | 10040 | 1.270 |
Why?
|
| Medication Reconciliation | 6 | 2023 | 18 | 1.240 |
Why?
|
| Clinical Pharmacy Information Systems | 12 | 2015 | 19 | 1.240 |
Why?
|
| Office Visits | 6 | 2026 | 81 | 1.220 |
Why?
|
| Delivery of Health Care, Integrated | 10 | 2020 | 144 | 1.220 |
Why?
|
| Commerce | 7 | 2021 | 58 | 1.220 |
Why?
|
| Medical Informatics Applications | 10 | 2020 | 20 | 1.220 |
Why?
|
| Surveys and Questionnaires | 41 | 2025 | 4008 | 1.210 |
Why?
|
| Workload | 10 | 2026 | 151 | 1.210 |
Why?
|
| Health Policy | 9 | 2022 | 225 | 1.210 |
Why?
|
| Professional Role | 7 | 2024 | 75 | 1.210 |
Why?
|
| Patient Access to Records | 5 | 2020 | 12 | 1.200 |
Why?
|
| Health Care Surveys | 21 | 2021 | 283 | 1.190 |
Why?
|
| Patient Care Planning | 8 | 2017 | 123 | 1.190 |
Why?
|
| Anaphylaxis | 4 | 2018 | 91 | 1.180 |
Why?
|
| Renal Insufficiency | 3 | 2021 | 250 | 1.180 |
Why?
|
| DNA, Bacterial | 10 | 2022 | 492 | 1.170 |
Why?
|
| Obesity | 10 | 2023 | 2377 | 1.160 |
Why?
|
| Diabetes Mellitus | 10 | 2022 | 884 | 1.160 |
Why?
|
| Health Priorities | 2 | 2019 | 41 | 1.150 |
Why?
|
| Gender Identity | 5 | 2024 | 74 | 1.150 |
Why?
|
| Health Services Research | 13 | 2017 | 177 | 1.150 |
Why?
|
| Language | 7 | 2024 | 217 | 1.120 |
Why?
|
| Medication Systems | 6 | 2015 | 7 | 1.110 |
Why?
|
| Sepsis | 8 | 2025 | 502 | 1.110 |
Why?
|
| Renal Insufficiency, Chronic | 11 | 2025 | 831 | 1.110 |
Why?
|
| Cohort Studies | 46 | 2024 | 5096 | 1.100 |
Why?
|
| Decision Making, Computer-Assisted | 7 | 2010 | 19 | 1.100 |
Why?
|
| Telephone | 4 | 2022 | 115 | 1.090 |
Why?
|
| Overweight | 5 | 2023 | 377 | 1.090 |
Why?
|
| Models, Theoretical | 7 | 2019 | 365 | 1.060 |
Why?
|
| Nursing Homes | 5 | 2024 | 90 | 1.060 |
Why?
|
| Hypotension | 2 | 2021 | 184 | 1.050 |
Why?
|
| Goals | 3 | 2025 | 125 | 1.050 |
Why?
|
| Medicare | 11 | 2023 | 434 | 1.040 |
Why?
|
| Job Satisfaction | 7 | 2026 | 98 | 1.030 |
Why?
|
| Organizational Culture | 4 | 2024 | 94 | 1.020 |
Why?
|
| Malpractice | 6 | 2022 | 59 | 1.010 |
Why?
|
| Medical Audit | 17 | 2017 | 96 | 1.000 |
Why?
|
| Clinical Laboratory Information Systems | 6 | 2017 | 9 | 1.000 |
Why?
|
| Clinical Alarms | 3 | 2016 | 9 | 0.990 |
Why?
|
| Diabetes Mellitus, Type 2 | 11 | 2024 | 1408 | 0.990 |
Why?
|
| Monitoring, Physiologic | 8 | 2025 | 376 | 0.980 |
Why?
|
| Surgical Procedures, Operative | 3 | 2024 | 228 | 0.970 |
Why?
|
| Palliative Care | 3 | 2025 | 442 | 0.970 |
Why?
|
| Computers, Handheld | 4 | 2015 | 32 | 0.970 |
Why?
|
| Software | 19 | 2022 | 752 | 0.970 |
Why?
|
| Pharmacovigilance | 4 | 2022 | 11 | 0.970 |
Why?
|
| Risk Assessment | 22 | 2025 | 3675 | 0.970 |
Why?
|
| Ficusin | 2 | 2024 | 5 | 0.960 |
Why?
|
| Health Information Exchange | 3 | 2023 | 10 | 0.960 |
Why?
|
| Length of Stay | 22 | 2025 | 1389 | 0.950 |
Why?
|
| Smartphone | 3 | 2020 | 46 | 0.950 |
Why?
|
| Interviews as Topic | 18 | 2025 | 438 | 0.950 |
Why?
|
| Databases, Factual | 16 | 2025 | 1220 | 0.950 |
Why?
|
| Hospital Administration | 5 | 2021 | 22 | 0.930 |
Why?
|
| Patients | 4 | 2024 | 123 | 0.930 |
Why?
|
| Medical Records | 14 | 2019 | 180 | 0.920 |
Why?
|
| Digital Divide | 2 | 2022 | 2 | 0.920 |
Why?
|
| Racism | 2 | 2023 | 43 | 0.920 |
Why?
|
| Health Care Reform | 6 | 2017 | 52 | 0.900 |
Why?
|
| Critical Care | 10 | 2023 | 678 | 0.900 |
Why?
|
| Venous Thromboembolism | 5 | 2025 | 179 | 0.890 |
Why?
|
| Medication Therapy Management | 2 | 2022 | 22 | 0.890 |
Why?
|
| Natural Language Processing | 11 | 2026 | 75 | 0.890 |
Why?
|
| Geriatrics | 1 | 2025 | 70 | 0.890 |
Why?
|
| United States Food and Drug Administration | 7 | 2018 | 156 | 0.880 |
Why?
|
| Pharmaceutical Services | 5 | 2021 | 35 | 0.880 |
Why?
|
| Risk Factors | 51 | 2025 | 10901 | 0.880 |
Why?
|
| Codeine | 1 | 2024 | 22 | 0.870 |
Why?
|
| Antifungal Agents | 5 | 2006 | 298 | 0.870 |
Why?
|
| Computer Security | 5 | 2018 | 28 | 0.870 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2014 | 15 | 0.870 |
Why?
|
| Computers | 8 | 2016 | 69 | 0.860 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2024 | 216 | 0.860 |
Why?
|
| Qualitative Research | 16 | 2025 | 695 | 0.850 |
Why?
|
| Subacute Care | 2 | 2021 | 8 | 0.850 |
Why?
|
| Databases as Topic | 2 | 2022 | 75 | 0.850 |
Why?
|
| Patient Transfer | 5 | 2025 | 109 | 0.840 |
Why?
|
| United Kingdom | 22 | 2024 | 249 | 0.840 |
Why?
|
| Precision Medicine | 6 | 2021 | 372 | 0.840 |
Why?
|
| Chromosome Segregation | 6 | 2017 | 71 | 0.840 |
Why?
|
| Hospital Communication Systems | 3 | 2016 | 6 | 0.830 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2025 | 176 | 0.820 |
Why?
|
| Postoperative Complications | 10 | 2024 | 3120 | 0.820 |
Why?
|
| Drug Therapy | 8 | 2008 | 83 | 0.820 |
Why?
|
| Long QT Syndrome | 1 | 2024 | 84 | 0.810 |
Why?
|
| Homes for the Aged | 2 | 2022 | 21 | 0.810 |
Why?
|
| Hyponatremia | 3 | 2016 | 74 | 0.800 |
Why?
|
| Monocytes | 1 | 2025 | 334 | 0.800 |
Why?
|
| Adolescent | 44 | 2025 | 20814 | 0.790 |
Why?
|
| Time Factors | 29 | 2026 | 6275 | 0.790 |
Why?
|
| Patient Outcome Assessment | 2 | 2021 | 92 | 0.780 |
Why?
|
| Replication Origin | 2 | 2015 | 12 | 0.780 |
Why?
|
| Hypernatremia | 2 | 2013 | 32 | 0.780 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2025 | 606 | 0.770 |
Why?
|
| Bibliometrics | 2 | 2017 | 39 | 0.770 |
Why?
|
| Peripheral Arterial Disease | 2 | 2025 | 313 | 0.770 |
Why?
|
| Rectum | 1 | 2023 | 101 | 0.760 |
Why?
|
| Incidence | 25 | 2025 | 3327 | 0.760 |
Why?
|
| Health Plan Implementation | 8 | 2022 | 42 | 0.760 |
Why?
|
| Global Health | 8 | 2023 | 631 | 0.760 |
Why?
|
| Regression Analysis | 11 | 2021 | 774 | 0.750 |
Why?
|
| Republic of Korea | 6 | 2025 | 56 | 0.750 |
Why?
|
| Clinical Laboratory Techniques | 9 | 2009 | 146 | 0.750 |
Why?
|
| Wounds and Injuries | 4 | 2020 | 393 | 0.750 |
Why?
|
| Antihypertensive Agents | 6 | 2024 | 421 | 0.750 |
Why?
|
| Bacteremia | 6 | 2015 | 423 | 0.740 |
Why?
|
| Rectal Neoplasms | 1 | 2023 | 76 | 0.730 |
Why?
|
| Neoplasms | 9 | 2025 | 2957 | 0.730 |
Why?
|
| Cooperative Behavior | 5 | 2019 | 224 | 0.730 |
Why?
|
| Health Services Misuse | 3 | 2017 | 24 | 0.730 |
Why?
|
| Genome-Wide Association Study | 4 | 2024 | 1834 | 0.720 |
Why?
|
| Acute Kidney Injury | 5 | 2021 | 677 | 0.720 |
Why?
|
| Somatoform Disorders | 4 | 2008 | 45 | 0.720 |
Why?
|
| Data Mining | 4 | 2024 | 62 | 0.710 |
Why?
|
| Neovascularization, Pathologic | 5 | 2024 | 237 | 0.710 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2013 | 133 | 0.710 |
Why?
|
| Perception | 5 | 2021 | 229 | 0.710 |
Why?
|
| Medication Adherence | 5 | 2022 | 333 | 0.710 |
Why?
|
| Retinal Neovascularization | 2 | 2025 | 12 | 0.700 |
Why?
|
| Socioeconomic Factors | 12 | 2022 | 896 | 0.700 |
Why?
|
| Transitional Care | 1 | 2021 | 17 | 0.700 |
Why?
|
| Program Evaluation | 5 | 2021 | 440 | 0.700 |
Why?
|
| Logistic Models | 20 | 2022 | 1822 | 0.690 |
Why?
|
| Patient Care Management | 5 | 2021 | 61 | 0.690 |
Why?
|
| Prescription Drugs | 3 | 2010 | 51 | 0.690 |
Why?
|
| Perioperative Care | 3 | 2024 | 215 | 0.690 |
Why?
|
| Multivariate Analysis | 24 | 2012 | 1395 | 0.680 |
Why?
|
| Pilot Projects | 17 | 2025 | 1441 | 0.680 |
Why?
|
| Fitness Trackers | 1 | 2020 | 15 | 0.680 |
Why?
|
| Healthcare Disparities | 7 | 2024 | 501 | 0.680 |
Why?
|
| Evidence-Based Medicine | 10 | 2024 | 642 | 0.680 |
Why?
|
| Decision Support Techniques | 9 | 2017 | 296 | 0.680 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 365 | 0.680 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 379 | 0.680 |
Why?
|
| Betacoronavirus | 3 | 2020 | 286 | 0.670 |
Why?
|
| Cost-Benefit Analysis | 15 | 2025 | 543 | 0.660 |
Why?
|
| Hospital Costs | 7 | 2014 | 179 | 0.660 |
Why?
|
| Health Facilities | 5 | 2024 | 68 | 0.660 |
Why?
|
| Health Services | 3 | 2006 | 68 | 0.660 |
Why?
|
| Health Care Sector | 2 | 2016 | 19 | 0.660 |
Why?
|
| Pressure Ulcer | 3 | 2021 | 73 | 0.650 |
Why?
|
| Biomedical Technology | 4 | 2023 | 39 | 0.650 |
Why?
|
| Health Behavior | 3 | 2020 | 390 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 13 | 2019 | 1302 | 0.640 |
Why?
|
| Drug Labeling | 3 | 2010 | 29 | 0.630 |
Why?
|
| Unnecessary Procedures | 5 | 2025 | 63 | 0.630 |
Why?
|
| Cognitive Dysfunction | 4 | 2025 | 348 | 0.630 |
Why?
|
| Patient Education as Topic | 8 | 2018 | 460 | 0.630 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 201 | 0.630 |
Why?
|
| Needs Assessment | 2 | 2020 | 172 | 0.620 |
Why?
|
| Hospitals, Urban | 7 | 2009 | 99 | 0.610 |
Why?
|
| Patient Readmission | 9 | 2025 | 417 | 0.610 |
Why?
|
| Specialization | 6 | 2012 | 75 | 0.610 |
Why?
|
| Cost Savings | 7 | 2023 | 78 | 0.610 |
Why?
|
| Reproducibility of Results | 17 | 2024 | 2950 | 0.600 |
Why?
|
| Professional Practice | 3 | 2019 | 40 | 0.600 |
Why?
|
| Comorbidity | 13 | 2020 | 1587 | 0.600 |
Why?
|
| Disease Management | 3 | 2014 | 559 | 0.600 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 931 | 0.590 |
Why?
|
| Knowledge Bases | 3 | 2025 | 40 | 0.590 |
Why?
|
| Anti-Infective Agents | 4 | 2017 | 265 | 0.590 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2019 | 217 | 0.590 |
Why?
|
| Economics, Behavioral | 1 | 2018 | 8 | 0.580 |
Why?
|
| Teaching Rounds | 1 | 2019 | 30 | 0.580 |
Why?
|
| Confidentiality | 6 | 2018 | 104 | 0.580 |
Why?
|
| Prevalence | 14 | 2024 | 2681 | 0.580 |
Why?
|
| Physicians, Family | 6 | 2009 | 38 | 0.570 |
Why?
|
| Intelligence | 1 | 2019 | 102 | 0.570 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2018 | 48 | 0.570 |
Why?
|
| Information Management | 4 | 2016 | 7 | 0.560 |
Why?
|
| Health Literacy | 2 | 2020 | 77 | 0.560 |
Why?
|
| Diagnostic Imaging | 4 | 2025 | 296 | 0.560 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 463 | 0.560 |
Why?
|
| Nurses | 6 | 2023 | 80 | 0.550 |
Why?
|
| Escherichia coli Proteins | 5 | 2015 | 310 | 0.550 |
Why?
|
| Kidney Diseases | 3 | 2024 | 483 | 0.550 |
Why?
|
| Internship and Residency | 10 | 2021 | 1207 | 0.540 |
Why?
|
| Sex Factors | 9 | 2020 | 1344 | 0.540 |
Why?
|
| Disease Models, Animal | 9 | 2025 | 4681 | 0.540 |
Why?
|
| Self Care | 6 | 2016 | 231 | 0.530 |
Why?
|
| Hospital Administrators | 2 | 2018 | 8 | 0.530 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2017 | 755 | 0.530 |
Why?
|
| Equipment Failure Analysis | 2 | 2018 | 83 | 0.520 |
Why?
|
| International Classification of Diseases | 5 | 2024 | 96 | 0.520 |
Why?
|
| Pain | 4 | 2024 | 438 | 0.520 |
Why?
|
| Medical History Taking | 5 | 2017 | 109 | 0.520 |
Why?
|
| Computer Systems | 6 | 2002 | 36 | 0.520 |
Why?
|
| Forecasting | 9 | 2022 | 365 | 0.520 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 66 | 0.510 |
Why?
|
| DNA | 4 | 2023 | 1444 | 0.510 |
Why?
|
| American Recovery and Reinvestment Act | 2 | 2022 | 6 | 0.510 |
Why?
|
| Colonic Neoplasms | 2 | 2023 | 262 | 0.510 |
Why?
|
| Feasibility Studies | 5 | 2024 | 821 | 0.510 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 683 | 0.510 |
Why?
|
| Weight Loss | 1 | 2020 | 511 | 0.510 |
Why?
|
| Odds Ratio | 12 | 2020 | 1233 | 0.500 |
Why?
|
| Arthroplasty, Replacement, Hip | 4 | 2022 | 111 | 0.500 |
Why?
|
| Vaccines | 1 | 2021 | 385 | 0.500 |
Why?
|
| Tertiary Care Centers | 6 | 2017 | 250 | 0.500 |
Why?
|
| Hospitals, Private | 1 | 2016 | 23 | 0.500 |
Why?
|
| Epidemics | 1 | 2017 | 59 | 0.500 |
Why?
|
| Clinical Decision-Making | 7 | 2024 | 310 | 0.500 |
Why?
|
| Value-Based Purchasing | 1 | 2016 | 2 | 0.490 |
Why?
|
| Hospitals, Public | 1 | 2016 | 49 | 0.490 |
Why?
|
| Research Personnel | 1 | 2017 | 136 | 0.490 |
Why?
|
| Nursing Informatics | 3 | 2020 | 4 | 0.490 |
Why?
|
| Endothelial Cells | 5 | 2025 | 536 | 0.480 |
Why?
|
| Mass Screening | 7 | 2024 | 824 | 0.480 |
Why?
|
| Total Quality Management | 4 | 2008 | 25 | 0.480 |
Why?
|
| Decision Making | 7 | 2021 | 680 | 0.480 |
Why?
|
| Education, Medical | 5 | 2024 | 288 | 0.480 |
Why?
|
| Research Design | 10 | 2023 | 722 | 0.480 |
Why?
|
| Systemic Inflammatory Response Syndrome | 5 | 2014 | 209 | 0.480 |
Why?
|
| Genetic Testing | 2 | 2013 | 1094 | 0.480 |
Why?
|
| Resource Allocation | 1 | 2016 | 52 | 0.480 |
Why?
|
| Organizational Case Studies | 10 | 2021 | 26 | 0.470 |
Why?
|
| Intention | 1 | 2016 | 100 | 0.460 |
Why?
|
| International Cooperation | 3 | 2020 | 162 | 0.460 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 292 | 0.460 |
Why?
|
| Students, Medical | 2 | 2019 | 340 | 0.460 |
Why?
|
| Hospitals, Psychiatric | 3 | 2018 | 70 | 0.460 |
Why?
|
| Datasets as Topic | 2 | 2018 | 102 | 0.460 |
Why?
|
| Infection Control | 2 | 2021 | 161 | 0.450 |
Why?
|
| Retinopathy of Prematurity | 1 | 2016 | 64 | 0.450 |
Why?
|
| Hemangioma | 1 | 2016 | 92 | 0.450 |
Why?
|
| Emergency Service, Hospital | 5 | 2025 | 1202 | 0.450 |
Why?
|
| Epinephrine | 1 | 2016 | 150 | 0.450 |
Why?
|
| Work Schedule Tolerance | 5 | 2021 | 41 | 0.450 |
Why?
|
| Cost of Illness | 4 | 2019 | 289 | 0.450 |
Why?
|
| Azoles | 2 | 2005 | 8 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2019 | 896 | 0.450 |
Why?
|
| Nursing Staff, Hospital | 5 | 2021 | 72 | 0.440 |
Why?
|
| Chromosomes | 2 | 2023 | 118 | 0.440 |
Why?
|
| Leadership | 7 | 2024 | 239 | 0.440 |
Why?
|
| Hospitals, General | 2 | 2025 | 24 | 0.440 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 23 | 0.440 |
Why?
|
| Hypnotics and Sedatives | 2 | 2013 | 133 | 0.440 |
Why?
|
| Patient Admission | 5 | 2024 | 182 | 0.440 |
Why?
|
| Exercise | 1 | 2020 | 865 | 0.440 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 144 | 0.430 |
Why?
|
| Hypoglycemic Agents | 8 | 2024 | 466 | 0.430 |
Why?
|
| Interprofessional Relations | 4 | 2018 | 152 | 0.430 |
Why?
|
| Medical Device Legislation | 1 | 2014 | 2 | 0.430 |
Why?
|
| Bacteria | 2 | 2015 | 530 | 0.430 |
Why?
|
| Feedback | 3 | 2021 | 149 | 0.430 |
Why?
|
| Culture | 1 | 2014 | 68 | 0.430 |
Why?
|
| Canada | 10 | 2024 | 322 | 0.430 |
Why?
|
| Depression | 3 | 2020 | 1325 | 0.430 |
Why?
|
| Bevacizumab | 1 | 2014 | 57 | 0.430 |
Why?
|
| Office Management | 2 | 2004 | 4 | 0.430 |
Why?
|
| Catheters, Indwelling | 1 | 2015 | 151 | 0.420 |
Why?
|
| Clinical Competence | 7 | 2018 | 1041 | 0.420 |
Why?
|
| Bioterrorism | 2 | 2004 | 10 | 0.420 |
Why?
|
| Computer Simulation | 2 | 2017 | 686 | 0.420 |
Why?
|
| Opioid-Related Disorders | 4 | 2024 | 293 | 0.420 |
Why?
|
| Homeostasis | 1 | 2018 | 713 | 0.420 |
Why?
|
| Origin Recognition Complex | 2 | 2013 | 2 | 0.420 |
Why?
|
| Personnel Staffing and Scheduling | 6 | 2019 | 82 | 0.420 |
Why?
|
| Cardiology | 1 | 2019 | 505 | 0.420 |
Why?
|
| Focus Groups | 5 | 2024 | 227 | 0.410 |
Why?
|
| DNA Topoisomerase IV | 1 | 2013 | 11 | 0.410 |
Why?
|
| Electronics | 6 | 2022 | 45 | 0.410 |
Why?
|
| Acute Coronary Syndrome | 2 | 2014 | 241 | 0.410 |
Why?
|
| Patient Handoff | 1 | 2013 | 23 | 0.410 |
Why?
|
| Periodicals as Topic | 3 | 2017 | 181 | 0.400 |
Why?
|
| Bayes Theorem | 2 | 2022 | 306 | 0.400 |
Why?
|
| Critical Illness | 2 | 2010 | 612 | 0.400 |
Why?
|
| Case-Control Studies | 13 | 2024 | 3433 | 0.400 |
Why?
|
| DNA-Binding Proteins | 5 | 2023 | 1951 | 0.400 |
Why?
|
| Hospital Charges | 6 | 2012 | 65 | 0.400 |
Why?
|
| Medical Record Linkage | 5 | 2014 | 10 | 0.400 |
Why?
|
| Observational Studies as Topic | 1 | 2013 | 97 | 0.400 |
Why?
|
| Computer Literacy | 3 | 2022 | 8 | 0.400 |
Why?
|
| Information Services | 4 | 2010 | 23 | 0.390 |
Why?
|
| Health Resources | 5 | 2017 | 128 | 0.390 |
Why?
|
| Efficiency, Organizational | 5 | 2022 | 57 | 0.390 |
Why?
|
| Disclosure | 1 | 2014 | 149 | 0.390 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2013 | 117 | 0.380 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 3067 | 0.380 |
Why?
|
| Speech Recognition Software | 3 | 2019 | 5 | 0.380 |
Why?
|
| Stereotyping | 2 | 2023 | 19 | 0.380 |
Why?
|
| Product Labeling | 1 | 2012 | 4 | 0.380 |
Why?
|
| Public Health | 3 | 2023 | 273 | 0.380 |
Why?
|
| Emergencies | 2 | 2004 | 180 | 0.380 |
Why?
|
| Pre-Eclampsia | 2 | 2025 | 223 | 0.380 |
Why?
|
| Policy Making | 3 | 2011 | 59 | 0.380 |
Why?
|
| Home Care Services | 2 | 2024 | 69 | 0.380 |
Why?
|
| Alternative Splicing | 1 | 2014 | 305 | 0.380 |
Why?
|
| Pediatrics | 5 | 2018 | 1228 | 0.380 |
Why?
|
| Community Health Services | 1 | 2013 | 92 | 0.380 |
Why?
|
| Nicotinic Agonists | 1 | 2012 | 33 | 0.380 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 2637 | 0.370 |
Why?
|
| Benzazepines | 1 | 2012 | 44 | 0.370 |
Why?
|
| Quinoxalines | 1 | 2012 | 39 | 0.370 |
Why?
|
| Health Planning | 2 | 2011 | 16 | 0.370 |
Why?
|
| Personal Satisfaction | 2 | 2023 | 102 | 0.370 |
Why?
|
| Vital Signs | 2 | 2021 | 25 | 0.370 |
Why?
|
| Fatigue Syndrome, Chronic | 4 | 1996 | 9 | 0.360 |
Why?
|
| Hospital Units | 3 | 2013 | 17 | 0.360 |
Why?
|
| Problem Solving | 1 | 2012 | 65 | 0.360 |
Why?
|
| Clinical Coding | 2 | 2015 | 16 | 0.360 |
Why?
|
| Population Surveillance | 5 | 2016 | 397 | 0.360 |
Why?
|
| Emotions | 1 | 2014 | 360 | 0.360 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2011 | 34 | 0.360 |
Why?
|
| Consumer Product Safety | 2 | 2010 | 29 | 0.360 |
Why?
|
| Blood Specimen Collection | 3 | 2017 | 46 | 0.360 |
Why?
|
| Diagnosis, Computer-Assisted | 5 | 2010 | 88 | 0.360 |
Why?
|
| Informatics | 2 | 2018 | 7 | 0.350 |
Why?
|
| Kidney Glomerulus | 2 | 2024 | 80 | 0.350 |
Why?
|
| Pharmacoepidemiology | 4 | 2018 | 10 | 0.350 |
Why?
|
| Coronary Artery Bypass | 5 | 2002 | 529 | 0.350 |
Why?
|
| Choroidal Neovascularization | 3 | 2025 | 21 | 0.350 |
Why?
|
| Penicillins | 2 | 2025 | 154 | 0.340 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 675 | 0.340 |
Why?
|
| Drug Information Services | 1 | 2010 | 5 | 0.340 |
Why?
|
| Amphotericin B | 2 | 2001 | 90 | 0.340 |
Why?
|
| DNA Damage | 4 | 2025 | 523 | 0.340 |
Why?
|
| Hospital Mortality | 8 | 2025 | 1069 | 0.340 |
Why?
|
| Pyridines | 1 | 2012 | 258 | 0.340 |
Why?
|
| Food Hypersensitivity | 3 | 2022 | 184 | 0.330 |
Why?
|
| Health Information Systems | 3 | 2016 | 31 | 0.330 |
Why?
|
| Hospitals, University | 7 | 2016 | 103 | 0.330 |
Why?
|
| Longitudinal Studies | 6 | 2026 | 1511 | 0.330 |
Why?
|
| Public Opinion | 3 | 2022 | 63 | 0.330 |
Why?
|
| Protein Isoforms | 6 | 2018 | 413 | 0.330 |
Why?
|
| Vancomycin | 4 | 2013 | 225 | 0.320 |
Why?
|
| Amiodarone | 2 | 2016 | 47 | 0.320 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2009 | 3 | 0.320 |
Why?
|
| Radiology Department, Hospital | 3 | 2025 | 25 | 0.320 |
Why?
|
| Anticoagulants | 6 | 2024 | 589 | 0.320 |
Why?
|
| Genomics | 4 | 2024 | 1617 | 0.320 |
Why?
|
| Economics, Hospital | 1 | 2009 | 7 | 0.320 |
Why?
|
| Age Factors | 8 | 2020 | 2866 | 0.320 |
Why?
|
| Technology | 4 | 2021 | 70 | 0.320 |
Why?
|
| Research | 5 | 2020 | 266 | 0.320 |
Why?
|
| Family | 5 | 2020 | 588 | 0.310 |
Why?
|
| Cell Cycle | 3 | 2015 | 600 | 0.310 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 671 | 0.310 |
Why?
|
| Fluconazole | 2 | 2006 | 48 | 0.310 |
Why?
|
| Meningioma | 2 | 2021 | 135 | 0.310 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 419 | 0.310 |
Why?
|
| Reference Books, Medical | 3 | 2006 | 4 | 0.310 |
Why?
|
| Pharyngitis | 2 | 2006 | 34 | 0.310 |
Why?
|
| Neovascularization, Physiologic | 2 | 2025 | 204 | 0.310 |
Why?
|
| Biomedical Research | 4 | 2010 | 555 | 0.310 |
Why?
|
| New England | 4 | 2019 | 11 | 0.310 |
Why?
|
| Therapeutics | 2 | 2007 | 7 | 0.300 |
Why?
|
| Therapeutic Human Experimentation | 1 | 2009 | 12 | 0.300 |
Why?
|
| Checklist | 3 | 2017 | 100 | 0.300 |
Why?
|
| Mental Disorders | 3 | 2008 | 889 | 0.300 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 821 | 0.300 |
Why?
|
| Genetic Variation | 1 | 2016 | 1559 | 0.300 |
Why?
|
| Models, Statistical | 3 | 2001 | 492 | 0.300 |
Why?
|
| Meningeal Neoplasms | 2 | 2021 | 203 | 0.300 |
Why?
|
| Social Values | 1 | 2009 | 46 | 0.300 |
Why?
|
| Cough | 3 | 2022 | 99 | 0.300 |
Why?
|
| Drug Utilization | 9 | 2015 | 164 | 0.300 |
Why?
|
| Blood | 4 | 2015 | 100 | 0.290 |
Why?
|
| Dementia | 3 | 2024 | 433 | 0.290 |
Why?
|
| Mycoses | 2 | 2006 | 112 | 0.290 |
Why?
|
| Alzheimer Disease | 3 | 2025 | 869 | 0.290 |
Why?
|
| Transcription, Genetic | 2 | 2025 | 1396 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 2849 | 0.290 |
Why?
|
| Terminology as Topic | 4 | 2015 | 227 | 0.290 |
Why?
|
| Kidney Transplantation | 1 | 2014 | 570 | 0.290 |
Why?
|
| Data Display | 2 | 2018 | 13 | 0.280 |
Why?
|
| Information Storage and Retrieval | 7 | 2008 | 61 | 0.280 |
Why?
|
| Personnel, Hospital | 5 | 2021 | 33 | 0.280 |
Why?
|
| Interrupted Time Series Analysis | 3 | 2025 | 26 | 0.280 |
Why?
|
| Chi-Square Distribution | 4 | 2020 | 567 | 0.270 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1976 | 0.270 |
Why?
|
| State Medicine | 4 | 2016 | 23 | 0.270 |
Why?
|
| Drug and Narcotic Control | 1 | 2007 | 16 | 0.270 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 5257 | 0.270 |
Why?
|
| Technology, Pharmaceutical | 1 | 2007 | 19 | 0.270 |
Why?
|
| Gynecology | 2 | 2009 | 128 | 0.270 |
Why?
|
| Efficiency | 3 | 2022 | 70 | 0.270 |
Why?
|
| England | 5 | 2019 | 58 | 0.260 |
Why?
|
| Heart Failure | 4 | 2016 | 2341 | 0.260 |
Why?
|
| United States Indian Health Service | 1 | 2007 | 1 | 0.260 |
Why?
|
| Phenotype | 4 | 2024 | 4493 | 0.260 |
Why?
|
| Wnt-5a Protein | 2 | 2025 | 23 | 0.260 |
Why?
|
| Patient Rights | 1 | 2007 | 50 | 0.260 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 2019 | 85 | 0.260 |
Why?
|
| Evaluation Studies as Topic | 5 | 2016 | 241 | 0.260 |
Why?
|
| Anthrax | 2 | 2004 | 30 | 0.260 |
Why?
|
| Delayed Diagnosis | 2 | 2025 | 129 | 0.260 |
Why?
|
| Anticonvulsants | 2 | 2003 | 384 | 0.260 |
Why?
|
| Psychotropic Drugs | 1 | 2008 | 123 | 0.250 |
Why?
|
| Nursing Records | 3 | 2020 | 5 | 0.250 |
Why?
|
| Platelet Transfusion | 1 | 2007 | 55 | 0.250 |
Why?
|
| Myocardial Infarction | 5 | 2014 | 993 | 0.250 |
Why?
|
| Blood Pressure | 4 | 2021 | 1352 | 0.250 |
Why?
|
| Antidepressive Agents | 2 | 2020 | 327 | 0.250 |
Why?
|
| Predictive Value of Tests | 11 | 2012 | 2287 | 0.250 |
Why?
|
| Online Systems | 1 | 2006 | 17 | 0.250 |
Why?
|
| Animals | 15 | 2025 | 34283 | 0.250 |
Why?
|
| Newspapers as Topic | 1 | 2006 | 6 | 0.250 |
Why?
|
| MEDLINE | 1 | 2006 | 18 | 0.250 |
Why?
|
| Acute Disease | 4 | 2018 | 1153 | 0.250 |
Why?
|
| Consumer Behavior | 4 | 2016 | 31 | 0.250 |
Why?
|
| Quality of Life | 5 | 2025 | 2096 | 0.250 |
Why?
|
| Systems Integration | 6 | 2020 | 25 | 0.250 |
Why?
|
| Random Allocation | 8 | 2018 | 421 | 0.240 |
Why?
|
| Mutagenesis | 3 | 2019 | 333 | 0.240 |
Why?
|
| Obstetrics | 2 | 2009 | 245 | 0.240 |
Why?
|
| Podocytes | 2 | 2024 | 76 | 0.240 |
Why?
|
| Directive Counseling | 1 | 2006 | 23 | 0.240 |
Why?
|
| Education, Medical, Continuing | 1 | 2007 | 132 | 0.240 |
Why?
|
| Smoking | 2 | 2010 | 925 | 0.240 |
Why?
|
| Mice | 11 | 2025 | 18414 | 0.240 |
Why?
|
| Sleep Deprivation | 3 | 2019 | 44 | 0.230 |
Why?
|
| Warfarin | 2 | 2021 | 123 | 0.230 |
Why?
|
| Prognosis | 9 | 2018 | 4930 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 7 | 2024 | 2558 | 0.230 |
Why?
|
| Erythrocyte Transfusion | 1 | 2007 | 142 | 0.230 |
Why?
|
| Treatment Outcome | 11 | 2024 | 12858 | 0.230 |
Why?
|
| Mortality | 3 | 2024 | 261 | 0.230 |
Why?
|
| Child Health Services | 2 | 2007 | 88 | 0.230 |
Why?
|
| Multienzyme Complexes | 1 | 2005 | 77 | 0.230 |
Why?
|
| Clinical Deterioration | 1 | 2025 | 14 | 0.230 |
Why?
|
| Transcription Termination, Genetic | 1 | 2025 | 13 | 0.230 |
Why?
|
| Residence Characteristics | 2 | 2019 | 291 | 0.230 |
Why?
|
| Radiologists | 1 | 2025 | 52 | 0.220 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2025 | 106 | 0.220 |
Why?
|
| Cell Movement | 2 | 2025 | 874 | 0.220 |
Why?
|
| Diagnostic Techniques and Procedures | 3 | 2012 | 33 | 0.220 |
Why?
|
| WT1 Proteins | 1 | 2024 | 22 | 0.220 |
Why?
|
| Chromosome Mapping | 2 | 2024 | 1067 | 0.220 |
Why?
|
| Analysis of Variance | 4 | 2016 | 955 | 0.220 |
Why?
|
| Cardiovascular Diseases | 4 | 2020 | 2076 | 0.220 |
Why?
|
| Torsades de Pointes | 1 | 2024 | 7 | 0.220 |
Why?
|
| Denmark | 3 | 2016 | 29 | 0.220 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 313 | 0.220 |
Why?
|
| Nursing Care | 1 | 2004 | 11 | 0.220 |
Why?
|
| Israel | 3 | 2016 | 48 | 0.220 |
Why?
|
| Psychiatry | 1 | 2008 | 270 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 109 | 0.220 |
Why?
|
| Radiology | 2 | 2023 | 124 | 0.220 |
Why?
|
| Cluster Analysis | 2 | 2022 | 419 | 0.220 |
Why?
|
| Wakefulness | 3 | 2021 | 102 | 0.220 |
Why?
|
| Metadata | 1 | 2024 | 6 | 0.220 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2021 | 47 | 0.210 |
Why?
|
| Coronary Disease | 3 | 2013 | 644 | 0.210 |
Why?
|
| DNA Repair | 3 | 2019 | 563 | 0.210 |
Why?
|
| Sulfonylurea Compounds | 1 | 2024 | 21 | 0.210 |
Why?
|
| Computer Communication Networks | 1 | 2004 | 17 | 0.210 |
Why?
|
| Surgery Department, Hospital | 2 | 2014 | 21 | 0.210 |
Why?
|
| Liver Function Tests | 2 | 2001 | 97 | 0.210 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2025 | 157 | 0.210 |
Why?
|
| Amyloid beta-Peptides | 1 | 2025 | 230 | 0.210 |
Why?
|
| Cephalosporins | 1 | 2025 | 137 | 0.210 |
Why?
|
| Pharmacies | 2 | 2001 | 15 | 0.210 |
Why?
|
| Near Miss, Healthcare | 2 | 2020 | 6 | 0.210 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2021 | 37 | 0.210 |
Why?
|
| Attitude to Health | 3 | 2018 | 251 | 0.210 |
Why?
|
| Health Services Needs and Demand | 3 | 2024 | 169 | 0.210 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2024 | 33 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 2 | 2006 | 235 | 0.210 |
Why?
|
| Mice, Nude | 2 | 2016 | 716 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1248 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2014 | 863 | 0.200 |
Why?
|
| Signal Transduction | 4 | 2024 | 4645 | 0.200 |
Why?
|
| Outpatient Clinics, Hospital | 5 | 2017 | 73 | 0.200 |
Why?
|
| Medical Oncology | 2 | 2021 | 237 | 0.200 |
Why?
|
| Antiviral Agents | 2 | 2006 | 811 | 0.200 |
Why?
|
| Uridine Triphosphate | 1 | 2023 | 9 | 0.200 |
Why?
|
| Uric Acid | 1 | 2024 | 110 | 0.200 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2019 | 139 | 0.200 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1904 | 0.200 |
Why?
|
| Demography | 1 | 2024 | 243 | 0.200 |
Why?
|
| Ownership | 2 | 2023 | 36 | 0.200 |
Why?
|
| Antimicrobial Stewardship | 1 | 2024 | 89 | 0.200 |
Why?
|
| Bronchial Spasm | 1 | 2022 | 3 | 0.200 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 647 | 0.200 |
Why?
|
| Group Practice | 1 | 2003 | 12 | 0.200 |
Why?
|
| Postoperative Period | 2 | 2021 | 333 | 0.200 |
Why?
|
| Hemodynamics | 2 | 2018 | 835 | 0.190 |
Why?
|
| Patient Selection | 3 | 2019 | 724 | 0.190 |
Why?
|
| ROC Curve | 6 | 2021 | 613 | 0.190 |
Why?
|
| Linear Models | 5 | 2022 | 694 | 0.190 |
Why?
|
| Access to Information | 2 | 2016 | 45 | 0.190 |
Why?
|
| Otitis Media with Effusion | 1 | 2023 | 30 | 0.190 |
Why?
|
| Central Nervous System Stimulants | 1 | 2023 | 127 | 0.190 |
Why?
|
| Influenza, Human | 2 | 2006 | 702 | 0.190 |
Why?
|
| Monte Carlo Method | 2 | 2021 | 101 | 0.190 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2002 | 31 | 0.190 |
Why?
|
| Genomic Instability | 2 | 2021 | 249 | 0.190 |
Why?
|
| RNA Splicing | 3 | 2018 | 234 | 0.190 |
Why?
|
| Cells, Cultured | 2 | 2025 | 2965 | 0.190 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 899 | 0.190 |
Why?
|
| Patient Identification Systems | 2 | 2014 | 3 | 0.190 |
Why?
|
| Microcomputers | 1 | 2002 | 12 | 0.190 |
Why?
|
| Otitis Media | 1 | 2023 | 89 | 0.190 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2022 | 23 | 0.190 |
Why?
|
| Therapy, Computer-Assisted | 2 | 1999 | 27 | 0.190 |
Why?
|
| Software Design | 3 | 2016 | 22 | 0.190 |
Why?
|
| Hearing Loss | 1 | 2024 | 210 | 0.180 |
Why?
|
| Socialization | 1 | 2022 | 18 | 0.180 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2004 | 226 | 0.180 |
Why?
|
| Telecommunications | 1 | 2002 | 21 | 0.180 |
Why?
|
| Glycocalyx | 1 | 2022 | 4 | 0.180 |
Why?
|
| Social Identification | 1 | 2022 | 20 | 0.180 |
Why?
|
| DnaB Helicases | 1 | 2021 | 1 | 0.180 |
Why?
|
| Physician's Role | 3 | 2012 | 164 | 0.180 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 2344 | 0.180 |
Why?
|
| Child | 16 | 2024 | 26098 | 0.180 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 160 | 0.180 |
Why?
|
| Disease Progression | 2 | 2019 | 2192 | 0.180 |
Why?
|
| Health Surveys | 5 | 2016 | 261 | 0.180 |
Why?
|
| Proportional Hazards Models | 5 | 2024 | 1401 | 0.180 |
Why?
|
| Registries | 5 | 2019 | 1591 | 0.180 |
Why?
|
| Radio Frequency Identification Device | 1 | 2021 | 3 | 0.180 |
Why?
|
| Capillaries | 1 | 2022 | 67 | 0.180 |
Why?
|
| Diverticulitis | 1 | 2021 | 7 | 0.180 |
Why?
|
| Hypochondriasis | 1 | 2001 | 1 | 0.180 |
Why?
|
| Prediabetic State | 1 | 2022 | 66 | 0.180 |
Why?
|
| Epidemiologic Studies | 1 | 2021 | 40 | 0.180 |
Why?
|
| Bias | 2 | 2021 | 143 | 0.180 |
Why?
|
| Rheumatic Diseases | 2 | 1999 | 78 | 0.180 |
Why?
|
| Fractures, Bone | 2 | 2020 | 200 | 0.180 |
Why?
|
| DNA Breaks, Double-Stranded | 3 | 2025 | 142 | 0.170 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2021 | 7 | 0.170 |
Why?
|
| Vocabulary, Controlled | 2 | 2018 | 11 | 0.170 |
Why?
|
| Physical Examination | 2 | 2000 | 169 | 0.170 |
Why?
|
| Drug Costs | 3 | 2015 | 62 | 0.170 |
Why?
|
| HLA-A Antigens | 1 | 2021 | 33 | 0.170 |
Why?
|
| Supratentorial Neoplasms | 1 | 2021 | 40 | 0.170 |
Why?
|
| HLA-B Antigens | 1 | 2021 | 30 | 0.170 |
Why?
|
| Europe | 1 | 2022 | 371 | 0.170 |
Why?
|
| Heart Arrest | 2 | 2025 | 375 | 0.170 |
Why?
|
| Potassium | 2 | 2019 | 269 | 0.170 |
Why?
|
| Consumer Advocacy | 1 | 2000 | 3 | 0.170 |
Why?
|
| Evidence-Based Nursing | 1 | 2020 | 4 | 0.170 |
Why?
|
| Minority Groups | 1 | 2023 | 256 | 0.170 |
Why?
|
| Fee-for-Service Plans | 2 | 2017 | 19 | 0.170 |
Why?
|
| Genome, Bacterial | 1 | 2022 | 209 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 18 | 0.170 |
Why?
|
| Mice, Knockout | 3 | 2025 | 3850 | 0.170 |
Why?
|
| Arterial Pressure | 1 | 2021 | 130 | 0.170 |
Why?
|
| Hypoglycemia | 1 | 2002 | 180 | 0.170 |
Why?
|
| Consensus | 5 | 2022 | 563 | 0.170 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 2122 | 0.170 |
Why?
|
| Cytotoxins | 1 | 2020 | 23 | 0.170 |
Why?
|
| Gout | 1 | 2024 | 173 | 0.170 |
Why?
|
| General Surgery | 2 | 2022 | 221 | 0.170 |
Why?
|
| Digestive System Diseases | 1 | 2001 | 23 | 0.170 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 237 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 1802 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 369 | 0.170 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2020 | 20 | 0.170 |
Why?
|
| Macular Degeneration | 1 | 2022 | 91 | 0.170 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 725 | 0.170 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2023 | 339 | 0.170 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 63 | 0.170 |
Why?
|
| Literature | 1 | 2000 | 4 | 0.160 |
Why?
|
| Interleukin-33 | 1 | 2020 | 19 | 0.160 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 290 | 0.160 |
Why?
|
| United States Agency for Healthcare Research and Quality | 3 | 2018 | 8 | 0.160 |
Why?
|
| Societies, Medical | 2 | 2006 | 788 | 0.160 |
Why?
|
| Patient Preference | 2 | 2019 | 147 | 0.160 |
Why?
|
| Software Validation | 2 | 2003 | 9 | 0.160 |
Why?
|
| Abdomen | 1 | 2001 | 132 | 0.160 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2020 | 20 | 0.160 |
Why?
|
| Consumer Health Informatics | 1 | 2020 | 1 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2025 | 761 | 0.160 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2020 | 14 | 0.160 |
Why?
|
| Foreign Bodies | 1 | 2021 | 103 | 0.160 |
Why?
|
| Retinal Vessels | 1 | 2020 | 52 | 0.160 |
Why?
|
| Paroxetine | 1 | 2020 | 24 | 0.160 |
Why?
|
| Psychometrics | 5 | 2024 | 666 | 0.160 |
Why?
|
| Photography | 1 | 2020 | 80 | 0.160 |
Why?
|
| Work | 1 | 2020 | 12 | 0.160 |
Why?
|
| Hospital Bed Capacity, 100 to 299 | 2 | 2012 | 2 | 0.160 |
Why?
|
| Bone Density | 1 | 2002 | 360 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 230 | 0.160 |
Why?
|
| Antibodies, Antinuclear | 1 | 1999 | 31 | 0.160 |
Why?
|
| Laboratories | 2 | 2017 | 84 | 0.160 |
Why?
|
| Probability | 5 | 2004 | 310 | 0.160 |
Why?
|
| Transsexualism | 1 | 2019 | 14 | 0.160 |
Why?
|
| Sertraline | 1 | 2020 | 45 | 0.160 |
Why?
|
| Recombination, Genetic | 3 | 2016 | 426 | 0.160 |
Why?
|
| Inservice Training | 2 | 2017 | 55 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 243 | 0.160 |
Why?
|
| Information Technology | 1 | 2019 | 9 | 0.160 |
Why?
|
| Capitation Fee | 1 | 1999 | 3 | 0.160 |
Why?
|
| Hospital Bed Capacity | 1 | 2019 | 28 | 0.150 |
Why?
|
| Developing Countries | 2 | 2013 | 303 | 0.150 |
Why?
|
| Motivation | 1 | 2022 | 334 | 0.150 |
Why?
|
| Writing | 1 | 2000 | 60 | 0.150 |
Why?
|
| Equipment Failure | 2 | 2018 | 130 | 0.150 |
Why?
|
| Serologic Tests | 1 | 1999 | 125 | 0.150 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 134 | 0.150 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1315 | 0.150 |
Why?
|
| Rural Population | 2 | 2020 | 256 | 0.150 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 58 | 0.150 |
Why?
|
| Creatinine | 2 | 2018 | 402 | 0.150 |
Why?
|
| Economics, Medical | 1 | 2018 | 7 | 0.150 |
Why?
|
| DNA, Cruciform | 2 | 2016 | 18 | 0.150 |
Why?
|
| Cholangiocarcinoma | 1 | 2020 | 125 | 0.150 |
Why?
|
| Faculty, Medical | 2 | 2019 | 267 | 0.150 |
Why?
|
| Laboratories, Hospital | 4 | 2017 | 24 | 0.150 |
Why?
|
| Speech | 1 | 2019 | 70 | 0.150 |
Why?
|
| Lipids | 1 | 2022 | 567 | 0.150 |
Why?
|
| Limulus Test | 1 | 1998 | 1 | 0.150 |
Why?
|
| Statistics, Nonparametric | 3 | 2020 | 429 | 0.150 |
Why?
|
| Electrocardiography | 1 | 2024 | 980 | 0.150 |
Why?
|
| Ancillary Services, Hospital | 1 | 1998 | 1 | 0.140 |
Why?
|
| Intestines | 1 | 2023 | 585 | 0.140 |
Why?
|
| Hospitalists | 1 | 1999 | 46 | 0.140 |
Why?
|
| Child, Preschool | 8 | 2016 | 14945 | 0.140 |
Why?
|
| Counseling | 2 | 2018 | 237 | 0.140 |
Why?
|
| Public Policy | 1 | 2018 | 54 | 0.140 |
Why?
|
| Conflict of Interest | 2 | 2014 | 65 | 0.140 |
Why?
|
| Causality | 3 | 2023 | 90 | 0.140 |
Why?
|
| Observation | 2 | 2016 | 39 | 0.140 |
Why?
|
| Endotoxins | 1 | 1998 | 50 | 0.140 |
Why?
|
| Renal Circulation | 1 | 2018 | 40 | 0.140 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2019 | 167 | 0.140 |
Why?
|
| Operating Rooms | 2 | 2015 | 76 | 0.140 |
Why?
|
| Hypercholesterolemia | 1 | 2001 | 234 | 0.140 |
Why?
|
| Forms and Records Control | 3 | 2015 | 9 | 0.140 |
Why?
|
| Anus Neoplasms | 1 | 2018 | 43 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2023 | 1680 | 0.140 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 142 | 0.140 |
Why?
|
| Terminal Care | 1 | 2019 | 113 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2C19 Inhibitors | 1 | 2017 | 2 | 0.140 |
Why?
|
| Infant | 6 | 2016 | 13210 | 0.140 |
Why?
|
| Biological Assay | 1 | 2018 | 108 | 0.140 |
Why?
|
| Fungemia | 1 | 1997 | 22 | 0.140 |
Why?
|
| Microvessels | 1 | 2018 | 66 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2024 | 1741 | 0.140 |
Why?
|
| Endothelium, Vascular | 2 | 2022 | 470 | 0.140 |
Why?
|
| Ticlopidine | 1 | 2017 | 28 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2017 | 25 | 0.140 |
Why?
|
| Radiography, Abdominal | 1 | 1997 | 46 | 0.140 |
Why?
|
| Microcirculation | 1 | 2018 | 111 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2022 | 389 | 0.130 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2017 | 11 | 0.130 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 131 | 0.130 |
Why?
|
| Fever | 2 | 2012 | 311 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 3 | 2021 | 298 | 0.130 |
Why?
|
| Patient Advocacy | 1 | 2017 | 60 | 0.130 |
Why?
|
| Transcriptome | 1 | 2024 | 1144 | 0.130 |
Why?
|
| Stroke | 4 | 2017 | 1041 | 0.130 |
Why?
|
| Program Development | 2 | 2017 | 184 | 0.130 |
Why?
|
| Sex Distribution | 3 | 2013 | 322 | 0.130 |
Why?
|
| Disease | 1 | 2018 | 125 | 0.130 |
Why?
|
| Utilization Review | 4 | 2015 | 40 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1249 | 0.130 |
Why?
|
| Risk | 6 | 2018 | 738 | 0.130 |
Why?
|
| Ischemia | 1 | 2020 | 353 | 0.130 |
Why?
|
| Politics | 1 | 2017 | 59 | 0.130 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 79 | 0.130 |
Why?
|
| Urinary Tract Infections | 2 | 2015 | 324 | 0.130 |
Why?
|
| Angioplasty | 1 | 1997 | 66 | 0.130 |
Why?
|
| DNA Breaks, Single-Stranded | 1 | 2016 | 19 | 0.130 |
Why?
|
| Benchmarking | 3 | 2003 | 137 | 0.130 |
Why?
|
| Text Messaging | 1 | 2017 | 39 | 0.130 |
Why?
|
| Neuropsychological Tests | 3 | 2025 | 990 | 0.130 |
Why?
|
| Infant, Newborn | 5 | 2023 | 8542 | 0.130 |
Why?
|
| Cell Division | 2 | 2019 | 723 | 0.130 |
Why?
|
| Bacterial Proteins | 4 | 2019 | 931 | 0.130 |
Why?
|
| Saudi Arabia | 1 | 2016 | 43 | 0.130 |
Why?
|
| Asthma, Aspirin-Induced | 1 | 2016 | 7 | 0.130 |
Why?
|
| Pericytes | 1 | 2016 | 27 | 0.120 |
Why?
|
| Nasal Polyps | 1 | 2016 | 28 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 3397 | 0.120 |
Why?
|
| Remote Sensing Technology | 1 | 2016 | 5 | 0.120 |
Why?
|
| RecQ Helicases | 1 | 2016 | 63 | 0.120 |
Why?
|
| Prescriptions | 1 | 2016 | 44 | 0.120 |
Why?
|
| Hemorrhage | 3 | 2022 | 501 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 1413 | 0.120 |
Why?
|
| Lead Poisoning | 1 | 2016 | 5 | 0.120 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2016 | 50 | 0.120 |
Why?
|
| Reimbursement, Incentive | 2 | 2017 | 48 | 0.120 |
Why?
|
| Hospitals, Special | 1 | 2016 | 12 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 298 | 0.120 |
Why?
|
| Taiwan | 3 | 2021 | 63 | 0.120 |
Why?
|
| Administration, Intravenous | 2 | 2017 | 170 | 0.120 |
Why?
|
| Cell Differentiation | 3 | 2023 | 1942 | 0.120 |
Why?
|
| Preoperative Period | 2 | 2014 | 90 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2018 | 290 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 391 | 0.120 |
Why?
|
| Rec A Recombinases | 2 | 2010 | 27 | 0.120 |
Why?
|
| Pharmacopoeias as Topic | 2 | 2006 | 4 | 0.120 |
Why?
|
| Utah | 2 | 2019 | 83 | 0.120 |
Why?
|
| Regional Medical Programs | 2 | 2006 | 18 | 0.120 |
Why?
|
| Microbiological Techniques | 2 | 2015 | 33 | 0.120 |
Why?
|
| HeLa Cells | 2 | 2014 | 694 | 0.120 |
Why?
|
| Health Information Management | 1 | 2015 | 5 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 939 | 0.120 |
Why?
|
| Disinfection | 1 | 2015 | 26 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2018 | 350 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 4739 | 0.120 |
Why?
|
| Streptococcus pyogenes | 2 | 2006 | 81 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2575 | 0.120 |
Why?
|
| Frail Elderly | 1 | 2016 | 105 | 0.120 |
Why?
|
| Allergens | 4 | 2022 | 352 | 0.120 |
Why?
|
| Phlebotomy | 2 | 2017 | 20 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 1271 | 0.120 |
Why?
|
| Data Accuracy | 1 | 2015 | 31 | 0.120 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2015 | 8 | 0.110 |
Why?
|
| Arginase | 1 | 2015 | 37 | 0.110 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 355 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 43 | 0.110 |
Why?
|
| Fatigue | 2 | 2009 | 199 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2017 | 356 | 0.110 |
Why?
|
| Interleukin-4 | 1 | 2015 | 144 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 991 | 0.110 |
Why?
|
| Quality Control | 3 | 2009 | 118 | 0.110 |
Why?
|
| Reimbursement Mechanisms | 1 | 2015 | 36 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 632 | 0.110 |
Why?
|
| Equipment Safety | 1 | 2014 | 37 | 0.110 |
Why?
|
| Mental Health Services | 1 | 2018 | 266 | 0.110 |
Why?
|
| National Health Programs | 2 | 2013 | 20 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 330 | 0.110 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 2014 | 7 | 0.110 |
Why?
|
| Capacity Building | 2 | 2013 | 26 | 0.110 |
Why?
|
| Military Nursing | 1 | 2014 | 1 | 0.110 |
Why?
|
| Social Support | 1 | 2017 | 374 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 1997 | 459 | 0.110 |
Why?
|
| Self Report | 1 | 2017 | 557 | 0.110 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 229 | 0.110 |
Why?
|
| Sleep | 4 | 2021 | 374 | 0.110 |
Why?
|
| Semantics | 1 | 2014 | 26 | 0.110 |
Why?
|
| Task Performance and Analysis | 3 | 2020 | 82 | 0.110 |
Why?
|
| Health Status | 1 | 1996 | 387 | 0.110 |
Why?
|
| Planning Techniques | 2 | 2004 | 6 | 0.110 |
Why?
|
| Anesthetics | 1 | 2015 | 78 | 0.110 |
Why?
|
| Japan | 4 | 2016 | 173 | 0.110 |
Why?
|
| Diagnosis-Related Groups | 4 | 2014 | 28 | 0.110 |
Why?
|
| Insurance Claim Reporting | 1 | 2013 | 7 | 0.110 |
Why?
|
| Respiratory Rate | 1 | 2013 | 7 | 0.110 |
Why?
|
| Nurse Practitioners | 1 | 2014 | 50 | 0.100 |
Why?
|
| Netherlands | 3 | 2020 | 48 | 0.100 |
Why?
|
| Accreditation | 1 | 2014 | 88 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2001 | 744 | 0.100 |
Why?
|
| Self Administration | 1 | 2014 | 49 | 0.100 |
Why?
|
| Costs and Cost Analysis | 6 | 2012 | 155 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 216 | 0.100 |
Why?
|
| Heterografts | 1 | 2014 | 194 | 0.100 |
Why?
|
| Clinical Medicine | 1 | 1994 | 21 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 363 | 0.100 |
Why?
|
| Proxy | 1 | 2014 | 21 | 0.100 |
Why?
|
| Sister Chromatid Exchange | 1 | 2013 | 15 | 0.100 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2013 | 26 | 0.100 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 28 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 330 | 0.100 |
Why?
|
| Certification | 1 | 2014 | 69 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2013 | 62 | 0.100 |
Why?
|
| Apoptosis | 1 | 2020 | 1853 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2015 | 112 | 0.100 |
Why?
|
| Narcotics | 1 | 2013 | 58 | 0.100 |
Why?
|
| Streptococcal Infections | 2 | 2006 | 248 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2014 | 146 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2015 | 137 | 0.100 |
Why?
|
| Hospital-Patient Relations | 1 | 2013 | 3 | 0.100 |
Why?
|
| Perioperative Period | 1 | 2013 | 51 | 0.100 |
Why?
|
| Cicatrix | 1 | 2014 | 125 | 0.100 |
Why?
|
| Insurance, Health | 2 | 2012 | 140 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2014 | 173 | 0.100 |
Why?
|
| Triage | 1 | 2014 | 152 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2015 | 463 | 0.100 |
Why?
|
| Feedback, Psychological | 1 | 2012 | 9 | 0.100 |
Why?
|
| Hospital Bed Capacity, 500 and over | 3 | 1997 | 11 | 0.100 |
Why?
|
| Clinical Audit | 2 | 2026 | 5 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 611 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 738 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 168 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 575 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 756 | 0.100 |
Why?
|
| Varenicline | 1 | 2012 | 12 | 0.100 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 415 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1227 | 0.090 |
Why?
|
| Communication Barriers | 2 | 2024 | 41 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2013 | 76 | 0.090 |
Why?
|
| Family Health | 1 | 2013 | 249 | 0.090 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2022 | 18 | 0.090 |
Why?
|
| Oxygen | 1 | 2016 | 555 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2019 | 2430 | 0.090 |
Why?
|
| Statistics as Topic | 4 | 2017 | 243 | 0.090 |
Why?
|
| Mutation | 7 | 2024 | 6144 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1278 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 189 | 0.090 |
Why?
|
| Numbers Needed To Treat | 1 | 2011 | 3 | 0.090 |
Why?
|
| Equipment Design | 2 | 2005 | 584 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2014 | 802 | 0.090 |
Why?
|
| Morbidity | 1 | 2012 | 258 | 0.090 |
Why?
|
| Automation | 1 | 2012 | 67 | 0.090 |
Why?
|
| Stakeholder Participation | 2 | 2022 | 36 | 0.090 |
Why?
|
| Viral Proteins | 1 | 2013 | 339 | 0.090 |
Why?
|
| Time and Motion Studies | 3 | 2018 | 17 | 0.090 |
Why?
|
| Acetaminophen | 1 | 2012 | 97 | 0.090 |
Why?
|
| Depressive Disorder | 3 | 2005 | 467 | 0.090 |
Why?
|
| Models, Biological | 3 | 2018 | 1389 | 0.090 |
Why?
|
| Liver Failure, Acute | 1 | 2012 | 96 | 0.090 |
Why?
|
| Australia | 3 | 1999 | 173 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3833 | 0.090 |
Why?
|
| Knowledge Management | 1 | 2011 | 2 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 690 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1348 | 0.090 |
Why?
|
| Robotics | 1 | 2012 | 106 | 0.090 |
Why?
|
| Macrophages | 1 | 2015 | 665 | 0.080 |
Why?
|
| Legislation, Drug | 1 | 2010 | 8 | 0.080 |
Why?
|
| Aerosols | 1 | 2010 | 60 | 0.080 |
Why?
|
| Heart Rate | 1 | 2013 | 578 | 0.080 |
Why?
|
| Pregnancy | 5 | 2025 | 7558 | 0.080 |
Why?
|
| Concept Formation | 1 | 2010 | 25 | 0.080 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2010 | 44 | 0.080 |
Why?
|
| Models, Genetic | 3 | 2011 | 750 | 0.080 |
Why?
|
| Nephrology | 3 | 2018 | 156 | 0.080 |
Why?
|
| Age Distribution | 2 | 2013 | 428 | 0.080 |
Why?
|
| Thymine | 1 | 2010 | 13 | 0.080 |
Why?
|
| Infant, Premature | 1 | 2016 | 848 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1617 | 0.080 |
Why?
|
| Switzerland | 1 | 2009 | 15 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2022 | 136 | 0.080 |
Why?
|
| Microbial Viability | 1 | 2010 | 42 | 0.080 |
Why?
|
| Central Nervous System Agents | 1 | 2009 | 15 | 0.080 |
Why?
|
| Research Support as Topic | 2 | 2009 | 61 | 0.080 |
Why?
|
| Nicotine | 1 | 2010 | 117 | 0.080 |
Why?
|
| Electronics, Medical | 1 | 2009 | 8 | 0.080 |
Why?
|
| Life Style | 1 | 2013 | 444 | 0.080 |
Why?
|
| Hospital Rapid Response Team | 1 | 2010 | 35 | 0.080 |
Why?
|
| Security Measures | 1 | 2009 | 5 | 0.080 |
Why?
|
| Rats | 1 | 2016 | 3457 | 0.080 |
Why?
|
| False Positive Reactions | 3 | 2006 | 142 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 505 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 211 | 0.080 |
Why?
|
| Protein Binding | 1 | 2013 | 1705 | 0.080 |
Why?
|
| Health Promotion | 1 | 2013 | 407 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 86 | 0.080 |
Why?
|
| Trust | 2 | 2013 | 80 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2024 | 1523 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2008 | 47 | 0.070 |
Why?
|
| Papanicolaou Test | 1 | 2008 | 32 | 0.070 |
Why?
|
| Observer Variation | 3 | 2018 | 317 | 0.070 |
Why?
|
| Renin-Angiotensin System | 2 | 2019 | 105 | 0.070 |
Why?
|
| Time | 2 | 2013 | 96 | 0.070 |
Why?
|
| Hospitals, Group Practice | 1 | 2008 | 2 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 158 | 0.070 |
Why?
|
| Diuretics | 2 | 2019 | 156 | 0.070 |
Why?
|
| World Health Organization | 3 | 2013 | 115 | 0.070 |
Why?
|
| Managed Care Programs | 2 | 1999 | 56 | 0.070 |
Why?
|
| Coronary Care Units | 1 | 2008 | 32 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 200 | 0.070 |
Why?
|
| Community Health Centers | 1 | 2008 | 37 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 26 | 0.070 |
Why?
|
| Multi-Institutional Systems | 2 | 2005 | 9 | 0.070 |
Why?
|
| Inventions | 2 | 2019 | 20 | 0.070 |
Why?
|
| China | 2 | 2022 | 286 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2008 | 197 | 0.070 |
Why?
|
| Financing, Government | 2 | 2009 | 32 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 106 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2012 | 271 | 0.070 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 1998 | 90 | 0.070 |
Why?
|
| Educational Status | 2 | 2010 | 281 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2009 | 513 | 0.070 |
Why?
|
| Systematized Nomenclature of Medicine | 2 | 2018 | 2 | 0.070 |
Why?
|
| Injury Severity Score | 2 | 2020 | 230 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2002 | 957 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2009 | 258 | 0.060 |
Why?
|
| Hospital Records | 2 | 1999 | 8 | 0.060 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 200 | 0.060 |
Why?
|
| Phenytoin | 2 | 1998 | 57 | 0.060 |
Why?
|
| Staff Development | 2 | 2019 | 47 | 0.060 |
Why?
|
| Truth Disclosure | 1 | 2008 | 108 | 0.060 |
Why?
|
| Informed Consent | 1 | 2009 | 343 | 0.060 |
Why?
|
| Rural Health Services | 1 | 2007 | 33 | 0.060 |
Why?
|
| Plasma | 1 | 2007 | 102 | 0.060 |
Why?
|
| Pharynx | 1 | 2006 | 64 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 1176 | 0.060 |
Why?
|
| Candida albicans | 1 | 2006 | 88 | 0.060 |
Why?
|
| MedlinePlus | 1 | 2006 | 1 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2007 | 87 | 0.060 |
Why?
|
| Emergency Treatment | 1 | 2007 | 85 | 0.060 |
Why?
|
| Professional-Family Relations | 2 | 2018 | 96 | 0.060 |
Why?
|
| Learning | 1 | 2009 | 369 | 0.060 |
Why?
|
| Bacteriological Techniques | 1 | 2006 | 86 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2006 | 350 | 0.060 |
Why?
|
| Georgia | 1 | 2025 | 43 | 0.060 |
Why?
|
| Candidiasis | 1 | 2006 | 132 | 0.060 |
Why?
|
| Flagellin | 1 | 2005 | 20 | 0.060 |
Why?
|
| S Phase | 1 | 2005 | 73 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2005 | 70 | 0.060 |
Why?
|
| Brain | 4 | 2025 | 3161 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 2 | 2018 | 72 | 0.060 |
Why?
|
| Public Health Informatics | 1 | 2005 | 1 | 0.060 |
Why?
|
| Neutropenia | 1 | 2006 | 205 | 0.060 |
Why?
|
| Urban Population | 2 | 2009 | 281 | 0.060 |
Why?
|
| DNA Polymerase III | 1 | 2025 | 24 | 0.060 |
Why?
|
| Adhesins, Bacterial | 1 | 2005 | 71 | 0.060 |
Why?
|
| Bacterial Adhesion | 1 | 2005 | 102 | 0.060 |
Why?
|
| Self-Assessment | 1 | 2005 | 59 | 0.060 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2025 | 78 | 0.060 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2024 | 24 | 0.060 |
Why?
|
| Capillary Permeability | 1 | 2025 | 72 | 0.060 |
Why?
|
| DNA, Single-Stranded | 1 | 2025 | 72 | 0.050 |
Why?
|
| Correspondence as Topic | 1 | 2004 | 12 | 0.050 |
Why?
|
| Microscopy | 1 | 2005 | 123 | 0.050 |
Why?
|
| Education, Nursing | 1 | 2004 | 18 | 0.050 |
Why?
|
| Diagnosis | 1 | 2024 | 33 | 0.050 |
Why?
|
| Insulin | 2 | 2016 | 1148 | 0.050 |
Why?
|
| Insurance Coverage | 2 | 2022 | 117 | 0.050 |
Why?
|
| Practice Management, Medical | 1 | 2004 | 8 | 0.050 |
Why?
|
| Norway | 1 | 2024 | 29 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1625 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 543 | 0.050 |
Why?
|
| Advance Care Planning | 1 | 2004 | 41 | 0.050 |
Why?
|
| Institutional Management Teams | 1 | 2003 | 2 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2003 | 16 | 0.050 |
Why?
|
| Speech Perception | 1 | 2024 | 57 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 1068 | 0.050 |
Why?
|
| Breast Diseases | 1 | 2004 | 38 | 0.050 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2024 | 23 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2024 | 191 | 0.050 |
Why?
|
| Prostate | 1 | 2006 | 415 | 0.050 |
Why?
|
| Ontario | 1 | 2004 | 87 | 0.050 |
Why?
|
| Mental Recall | 1 | 2024 | 142 | 0.050 |
Why?
|
| Colorado | 2 | 2018 | 19 | 0.050 |
Why?
|
| Shoulder Pain | 2 | 2001 | 21 | 0.050 |
Why?
|
| Cell Communication | 1 | 2024 | 196 | 0.050 |
Why?
|
| Social Responsibility | 1 | 2003 | 82 | 0.050 |
Why?
|
| Adrenomedullin | 1 | 2024 | 84 | 0.050 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2003 | 1 | 0.050 |
Why?
|
| Medicare Part B | 1 | 2003 | 2 | 0.050 |
Why?
|
| Mammography | 1 | 2004 | 130 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1135 | 0.050 |
Why?
|
| Management Information Systems | 1 | 2003 | 3 | 0.050 |
Why?
|
| Technology, Radiologic | 1 | 2023 | 11 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 33 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 768 | 0.050 |
Why?
|
| tau Proteins | 1 | 2025 | 253 | 0.050 |
Why?
|
| Hydroxylamines | 1 | 2022 | 7 | 0.050 |
Why?
|
| Heel | 1 | 2002 | 9 | 0.050 |
Why?
|
| Cytidine | 1 | 2022 | 12 | 0.050 |
Why?
|
| Hip | 1 | 2002 | 20 | 0.050 |
Why?
|
| Ivermectin | 1 | 2022 | 8 | 0.050 |
Why?
|
| Medicare Part C | 1 | 2003 | 35 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2022 | 19 | 0.050 |
Why?
|
| Off-Label Use | 1 | 2022 | 26 | 0.050 |
Why?
|
| Tretinoin | 1 | 2023 | 96 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2023 | 72 | 0.050 |
Why?
|
| Respiratory Sounds | 1 | 2022 | 79 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1892 | 0.050 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2022 | 34 | 0.050 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 53 | 0.050 |
Why?
|
| Bruch Membrane | 1 | 2022 | 2 | 0.050 |
Why?
|
| CD18 Antigens | 1 | 2002 | 44 | 0.050 |
Why?
|
| Quarantine | 1 | 2022 | 18 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2002 | 197 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2024 | 313 | 0.050 |
Why?
|
| Polymorphism, Genetic | 2 | 2002 | 794 | 0.050 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2002 | 72 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 704 | 0.050 |
Why?
|
| Choroid | 1 | 2022 | 23 | 0.050 |
Why?
|
| Spine | 1 | 2002 | 146 | 0.040 |
Why?
|
| New Jersey | 1 | 2021 | 25 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2001 | 78 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2001 | 117 | 0.040 |
Why?
|
| Endothelium | 1 | 2022 | 64 | 0.040 |
Why?
|
| Aspirin | 1 | 2023 | 213 | 0.040 |
Why?
|
| Morphine | 1 | 2021 | 80 | 0.040 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2001 | 32 | 0.040 |
Why?
|
| Joint Diseases | 1 | 2001 | 32 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 35 | 0.040 |
Why?
|
| Lasers | 1 | 2022 | 114 | 0.040 |
Why?
|
| Nurse's Role | 2 | 2014 | 40 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 2021 | 56 | 0.040 |
Why?
|
| Societies, Pharmaceutical | 1 | 2021 | 14 | 0.040 |
Why?
|
| Strategic Planning | 1 | 2021 | 6 | 0.040 |
Why?
|
| Biomarkers | 2 | 2025 | 3365 | 0.040 |
Why?
|
| Case Management | 1 | 2001 | 17 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2022 | 67 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2001 | 58 | 0.040 |
Why?
|
| Nursing Research | 1 | 2021 | 17 | 0.040 |
Why?
|
| New York City | 1 | 2021 | 64 | 0.040 |
Why?
|
| Nizatidine | 1 | 2000 | 4 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 51 | 0.040 |
Why?
|
| Musculoskeletal Diseases | 2 | 2001 | 55 | 0.040 |
Why?
|
| Spirometry | 1 | 2021 | 91 | 0.040 |
Why?
|
| Digestive System | 1 | 2001 | 61 | 0.040 |
Why?
|
| Ondansetron | 1 | 2000 | 8 | 0.040 |
Why?
|
| California | 1 | 2021 | 126 | 0.040 |
Why?
|
| Research Report | 1 | 2021 | 71 | 0.040 |
Why?
|
| Colectomy | 1 | 2021 | 94 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2008 | 409 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2000 | 5 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 157 | 0.040 |
Why?
|
| MEDLARS | 1 | 2000 | 1 | 0.040 |
Why?
|
| Minnesota | 1 | 2000 | 179 | 0.040 |
Why?
|
| Rheumatoid Factor | 1 | 1999 | 6 | 0.040 |
Why?
|
| RNA, Bacterial | 1 | 2000 | 57 | 0.040 |
Why?
|
| APACHE | 2 | 2013 | 50 | 0.040 |
Why?
|
| Knee Injuries | 1 | 2000 | 40 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 1999 | 58 | 0.040 |
Why?
|
| Risk Sharing, Financial | 1 | 1999 | 2 | 0.040 |
Why?
|
| Integrated Advanced Information Management Systems | 1 | 1999 | 1 | 0.040 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 45 | 0.040 |
Why?
|
| Multitasking Behavior | 1 | 2019 | 1 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2021 | 237 | 0.040 |
Why?
|
| North America | 1 | 2020 | 256 | 0.040 |
Why?
|
| Heparin | 1 | 2000 | 208 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 1999 | 26 | 0.040 |
Why?
|
| Sigma Factor | 1 | 2019 | 36 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2018 | 33 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 710 | 0.040 |
Why?
|
| Delphi Technique | 2 | 2013 | 258 | 0.040 |
Why?
|
| Actigraphy | 1 | 2019 | 49 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 97 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2019 | 67 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 297 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 60 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 61 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2021 | 307 | 0.040 |
Why?
|
| Hydrostatic Pressure | 1 | 2018 | 10 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2018 | 50 | 0.040 |
Why?
|
| Leucovorin | 1 | 2018 | 54 | 0.040 |
Why?
|
| Models, Organizational | 1 | 2018 | 44 | 0.040 |
Why?
|
| Tryptases | 1 | 2018 | 17 | 0.040 |
Why?
|
| Classification | 1 | 2018 | 18 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2018 | 24 | 0.040 |
Why?
|
| Nursing Administration Research | 2 | 2008 | 2 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2020 | 150 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2018 | 38 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2018 | 134 | 0.040 |
Why?
|
| Hospital-Physician Joint Ventures | 1 | 1998 | 1 | 0.040 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2018 | 40 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 1998 | 72 | 0.030 |
Why?
|
| Belgium | 1 | 2018 | 44 | 0.030 |
Why?
|
| Information Seeking Behavior | 1 | 2018 | 17 | 0.030 |
Why?
|
| Health Level Seven | 1 | 2017 | 3 | 0.030 |
Why?
|
| Rheumatology | 1 | 1999 | 128 | 0.030 |
Why?
|
| Plasmids | 2 | 2000 | 455 | 0.030 |
Why?
|
| Databases, Pharmaceutical | 1 | 2017 | 6 | 0.030 |
Why?
|
| Cognition | 1 | 2023 | 837 | 0.030 |
Why?
|
| Urinalysis | 1 | 2018 | 73 | 0.030 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2017 | 9 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2017 | 27 | 0.030 |
Why?
|
| Radioallergosorbent Test | 1 | 2017 | 9 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 185 | 0.030 |
Why?
|
| State Government | 1 | 2017 | 29 | 0.030 |
Why?
|
| Shellfish | 1 | 2017 | 21 | 0.030 |
Why?
|
| Hyperkalemia | 1 | 2018 | 70 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 698 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 431 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 76 | 0.030 |
Why?
|
| Biopsy | 2 | 2014 | 1248 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 78 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 171 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 227 | 0.030 |
Why?
|
| Tobacco Use | 1 | 2017 | 31 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2016 | 31 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2018 | 218 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 362 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2017 | 53 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2017 | 243 | 0.030 |
Why?
|
| Indiana | 1 | 2016 | 5 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 790 | 0.030 |
Why?
|
| Quebec | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cardiology Service, Hospital | 1 | 1996 | 14 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 644 | 0.030 |
Why?
|
| Osteoarthritis, Knee | 1 | 2000 | 275 | 0.030 |
Why?
|
| Government | 1 | 2016 | 13 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1999 | 399 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 231 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 224 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 492 | 0.030 |
Why?
|
| Enzyme Multiplied Immunoassay Technique | 1 | 1995 | 1 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 513 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 286 | 0.030 |
Why?
|
| Phenobarbital | 1 | 1995 | 30 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1995 | 43 | 0.030 |
Why?
|
| Argentina | 1 | 2015 | 54 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 1998 | 272 | 0.030 |
Why?
|
| Drug Overdose | 1 | 2016 | 72 | 0.030 |
Why?
|
| Chromatin | 1 | 2018 | 491 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 1997 | 208 | 0.030 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2015 | 33 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2015 | 95 | 0.030 |
Why?
|
| Administrative Personnel | 1 | 2015 | 26 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 112 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1995 | 240 | 0.030 |
Why?
|
| Valproic Acid | 1 | 1995 | 161 | 0.030 |
Why?
|
| DNA Restriction Enzymes | 1 | 1994 | 74 | 0.030 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 284 | 0.030 |
Why?
|
| Afghanistan | 1 | 2014 | 16 | 0.030 |
Why?
|
| Los Angeles | 1 | 2014 | 17 | 0.030 |
Why?
|
| Grounded Theory | 1 | 2014 | 11 | 0.030 |
Why?
|
| Patient Compliance | 1 | 1998 | 468 | 0.030 |
Why?
|
| Collateral Circulation | 1 | 2014 | 41 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 703 | 0.030 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 35 | 0.030 |
Why?
|
| AIDS Dementia Complex | 1 | 1994 | 21 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2014 | 64 | 0.030 |
Why?
|
| Washington | 1 | 1994 | 36 | 0.030 |
Why?
|
| Women's Health Services | 1 | 1994 | 14 | 0.030 |
Why?
|
| Nalidixic Acid | 1 | 2013 | 3 | 0.030 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2013 | 16 | 0.030 |
Why?
|
| Insurance Carriers | 1 | 2013 | 6 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 1997 | 483 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2013 | 31 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2013 | 21 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 301 | 0.030 |
Why?
|
| Bacteriophage mu | 1 | 2013 | 12 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1994 | 101 | 0.030 |
Why?
|
| Synthetic Biology | 1 | 2013 | 14 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2014 | 200 | 0.030 |
Why?
|
| Psychological Tests | 1 | 1993 | 94 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 2014 | 79 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 747 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 2138 | 0.030 |
Why?
|
| Biometry | 1 | 1994 | 98 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 2095 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2013 | 88 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 188 | 0.020 |
Why?
|
| Body Weight | 1 | 2017 | 986 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1997 | 569 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 350 | 0.020 |
Why?
|
| Mental Health | 1 | 1996 | 382 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2012 | 42 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 1996 | 391 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 382 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 279 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2013 | 231 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 19 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 499 | 0.020 |
Why?
|
| Kidney | 1 | 2018 | 1300 | 0.020 |
Why?
|
| Retina | 1 | 2015 | 458 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2012 | 76 | 0.020 |
Why?
|
| Culture Media | 1 | 1992 | 174 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2012 | 51 | 0.020 |
Why?
|
| Liability, Legal | 1 | 2011 | 49 | 0.020 |
Why?
|
| Finland | 1 | 2011 | 46 | 0.020 |
Why?
|
| Latin America | 1 | 2011 | 101 | 0.020 |
Why?
|
| Computational Biology | 1 | 2016 | 870 | 0.020 |
Why?
|
| Swine | 1 | 2014 | 1188 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 588 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2010 | 22 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2010 | 148 | 0.020 |
Why?
|
| Epidemiology | 1 | 2009 | 8 | 0.020 |
Why?
|
| Family Practice | 1 | 2009 | 86 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 2358 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 135 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 741 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Proteins | 1 | 2013 | 1025 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 14 | 0.020 |
Why?
|
| Job Description | 1 | 2008 | 9 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2460 | 0.020 |
Why?
|
| Publishing | 1 | 2009 | 105 | 0.020 |
Why?
|
| Mentors | 1 | 2009 | 158 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 560 | 0.020 |
Why?
|
| Capital Expenditures | 1 | 2006 | 1 | 0.020 |
Why?
|
| State Health Plans | 1 | 2006 | 4 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2013 | 950 | 0.020 |
Why?
|
| Investments | 1 | 2006 | 11 | 0.020 |
Why?
|
| Budgets | 1 | 2006 | 16 | 0.020 |
Why?
|
| Genotype | 2 | 2002 | 2651 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1611 | 0.010 |
Why?
|
| Contraindications | 1 | 2005 | 77 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2007 | 190 | 0.010 |
Why?
|
| Community Networks | 1 | 2005 | 30 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 842 | 0.010 |
Why?
|
| Health Education | 1 | 2006 | 228 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2005 | 134 | 0.010 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 26 | 0.010 |
Why?
|
| Database Management Systems | 1 | 2003 | 27 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2002 | 138 | 0.010 |
Why?
|
| Shoulder Joint | 1 | 2001 | 31 | 0.010 |
Why?
|
| Coma | 1 | 1981 | 55 | 0.010 |
Why?
|
| Knee Joint | 1 | 2001 | 172 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2002 | 749 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2000 | 186 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2001 | 453 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2000 | 266 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 1490 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 1633 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 1705 | 0.010 |
Why?
|
| Exodeoxyribonuclease V | 1 | 1994 | 28 | 0.010 |
Why?
|
| Exodeoxyribonucleases | 1 | 1994 | 50 | 0.010 |
Why?
|
| Endodeoxyribonucleases | 1 | 1994 | 45 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1994 | 8 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1994 | 11 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 255 | 0.010 |
Why?
|
| Oximes | 1 | 1994 | 55 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 2781 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3610 | 0.000 |
Why?
|
| Hypoxia, Brain | 1 | 1981 | 34 | 0.000 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1981 | 64 | 0.000 |
Why?
|
| Neurologic Examination | 1 | 1981 | 196 | 0.000 |
Why?
|
| Brain Stem | 1 | 1981 | 110 | 0.000 |
Why?
|
| Hepatic Encephalopathy | 1 | 1981 | 82 | 0.000 |
Why?
|
| Cerebrovascular Disorders | 1 | 1981 | 115 | 0.000 |
Why?
|
| Brain Ischemia | 1 | 1981 | 261 | 0.000 |
Why?
|